Justin Budka
Overview
Explore the profile of Justin Budka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tian Y, Budka J, Locke F, Westin J, To C, Tiwari G, et al.
Front Oncol
. 2025 Mar;
15:1519473.
PMID: 40083872
Introduction: CAR T cell therapy provided transformative outcomes for patients with B-cell lymphoma; however, a large fraction of patients remains at risk for relapse, underlying the need to uncover mechanisms...
2.
Stewart C, Siegler E, Sakemura R, Cox M, Huynh T, Kimball B, et al.
Nat Commun
. 2024 Sep;
15(1):7921.
PMID: 39266501
Durable response to chimeric antigen receptor T (CART) cell therapy remains limited in part due to CART cell exhaustion. Here, we investigate the regulation of CART cell exhaustion with three...
3.
Maurer K, Grabski I, Houot R, Gohil S, Miura S, Redd R, et al.
Blood
. 2024 Sep;
144(24):2490-2502.
PMID: 39241199
Engineered cellular therapy with CD19-targeting chimeric antigen receptor T cells (CAR-Ts) has revolutionized outcomes for patients with relapsed/refractory large B-cell lymphoma (LBCL), but the cellular and molecular features associated with...
4.
Chartier M, Filosto S, Peyret T, Chiney M, Milletti F, Budka J, et al.
Clin Pharmacokinet
. 2024 Sep;
63(9):1283-1299.
PMID: 39240498
Background And Objective: Axicabtagene ciloleucel (axi-cel, Yescarta) is an autologous, anti-CD19, chimeric antigen receptor (CAR) T-cell therapy approved for patients with relapsed and refractory non-Hodgkin's lymphoma. Substantial inter-individual variability in...
5.
Locke F, Filosto S, Chou J, Vardhanabhuti S, Perbost R, Dreger P, et al.
Nat Med
. 2024 Jan;
30(2):507-518.
PMID: 38233586
The phase 3 ZUMA-7 trial in second-line large B cell lymphoma demonstrated superiority of anti-CD19 CAR T cell therapy (axicabtagene ciloleucel (axi-cel)) over standard of care (SOC; salvage chemotherapy followed...
6.
Filosto S, Vardhanabhuti S, Canales M, Poire X, Lekakis L, de Vos S, et al.
Blood Cancer Discov
. 2023 Nov;
5(1):21-33.
PMID: 37983485
Significance: In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower...
7.
Adelaiye-Ogala R, Budka J, Damayanti N, Arrington J, Ferris M, Hsu C, et al.
Cancer Res
. 2017 Oct;
77(23):6651-6666.
PMID: 28978636
Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represents a major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC). Recent reports suggest that drug...